January 4, 2018 / 5:44 PM / in 6 minutes BRIEF-Rhythm Pharmaceuticals Announces Progress In Clinical Development Of Setmelanotide Reuters Staff 1 Min Read 
Jan 4 (Reuters) - Rhythm Pharmaceuticals Inc: 
* RHYTHM PHARMACEUTICALS ANNOUNCES PROGRESS IN CLINICAL DEVELOPMENT OF SETMELANOTIDE FOR TREATMENT OF RARE GENETIC DISORDERS OF OBESITY 
* RHYTHM PHARMACEUTICALS - SETMELANOTIDE GRANTED ORPHAN DRUG DESIGNATION FOR TREATMENT OF LEPTIN RECEPTOR (LEPR) DEFICIENCY OBESITY 
* RHYTHM PHARMACEUTICALS - FINALIZED PROTOCOL FOR PIVOTAL PHASE 3 CLINICAL TRIAL IN PRO-OPIOMELANOCORTIN (POMC) DEFICIENCY OBESITY 
* RHYTHM PHARMACEUTICALS - CONFIRMS PLANS TO FILE NDA WITH FDA BASED ON ONE-YEAR DATA FROM 10 PATIENT COHORT IN POMC PHASE 3 CLINICAL TRIAL Source text for Eikon: Further company coverage: